TAI'AN, China, June 22, 2011 /PRNewswire-Asia-FirstCall/ --
China Biologic Products, Inc. (Nasdaq: CBPO) ("China Biologic," or
the "Company"), a leading plasma-based biopharmaceutical company in
China, today announced that it
will present and meet with investors at the Brean Murray, Carret
& Co., 2011 Beijing China Growth Conference on June 27, 2011.
Mr. Stanley Lau, China Biologic's
President, and Mr. Y. Tristan Kuo,
Chief Financial Officer, will present the Company's strategy,
products, markets, and outlook on June
27 at 9:20 a.m. in the JW
Marriott Hotel Beijing, 83 Jian Guo Road, Chaoyang District,
Beijing.
Investors interested in attending the conference and meeting
with China Biologic should contact their Brean Murray, Carret
representative.
About China Biologic Products, Inc.
China Biologic Products, Inc., through its indirect
majority-owned subsidiaries, Shandong Taibang Biological Products
Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. and its
equity investment in Xi'an Huitian Blood Products Co., Ltd., is
currently one of the leading plasma-based biopharmaceutical
companies in China. The Company is
a fully integrated biologic products company with plasma
collection, production and manufacturing, research and development
and commercial operations. The Company's plasma-based
biopharmaceutical products are irreplaceable during medical
emergencies and are used for the prevention and treatment of
various diseases. The Company sells its products to hospitals and
other healthcare facilities in China. Please see the Company's website
http://www.chinabiologic.com for additional information.
Company Contact:
|
|
Mr. Y. Tristan Kuo
|
|
Chief Financial
Officer
|
|
China Biologic Products,
Inc.
|
|
Tel: +86 53 8620 2206
|
|
Email: IR@chinabiologic.com
|
|
www.chinabiologic.com
|
|
|
SOURCE China Biologic Products, Inc.